India Proposes Big Push To Pharma Manufacturing And Research; Talks On With Multinational Companies For Vaccine Development Center
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - The Indian government is moving swiftly on a series of new initiatives that seek to position India as a country of choice for big pharmaceutical companies looking to establish research centers and build manufacturing facilities. An outlay of $1 to $2 billion will be made every year through 2020 for the comprehensive action plan, if implemented
You may also be interested in...
Merck-Wellcome Joint Venture Ties Up With MEND To Focus On A Heat-Stable Rotavirus Vaccine For Developing Markets
On completion of Phase II efficacy studies, and once the prototype is in place, the JV, Hilleman Labs, will look at partnering for the manufacturing and commercialization phase.
Merck-Wellcome Joint Venture Ties Up With MEND To Focus On A Heat-Stable Rotavirus Vaccine For Developing Markets
On completion of Phase II efficacy studies, and once the prototype is in place, the JV, Hilleman Labs, will look at partnering for the manufacturing and commercialization phase.
Merck JV Ties Up With MEND To Focus On First Heat-stable Rotavirus Vaccine For Developing Markets
MUMBAI - Hilleman Laboratories - the nonprofit joint venture between Merck & Co. and Wellcome Trust to develop affordable vaccines for low-income countries - has set its sights on developing a heat-stable form of rotavirus vaccine as its first project